Evaluation of the relationship between anti-inflammatory cytokines and adverse cardiac remodeling after myocardial infarction

Aim    To clarify the role of interleukin (IL) – 10 and members of its subfamily (IL-19 and IL-26) in cardiac remodeling during the post-myocardial infarction (MI) period.
Material and methods    A total of 45 patients with ST-segment elevation MI were enrolled. Serum cytokine concentrations were measured at the first day and 14 days post-MI. Left ventricular (LV) reverse remodeling (RR) was defined as the reduction of LV end-diastolic volume or LV end-systolic volume by ≥ 12 % in cardiac magnetic resonance images at 6‑mo follow-up. A 12 % increase was defined as adverse remodeling (AR).
Results    The post-MI first-day median IL-10 (9.7 pg / ml vs. 17.6 pg / ml, p<0.001), median IL-19 (28.7 pg / ml vs. 36.9 pg / ml, p<0.001), and median IL-26 (47.8 pg / ml vs. 90.7 pg / ml, p<0.001) were lower in the RR group compared to the AR group. There was a significant decrease in the concentration of anti-inflammatory cytokines in the AR group from the first to the 14 days post-MI. However, no significant change was observed in the RR group. Regression analysis revealed that a low IL-10 concentration on the post-MI first day was related to RR (OR=0.76, p=0.035). A 1 % increase in change of IL-10 concentration increased the probability of RR by 1.07 times.
Conclusion    The concentrations of cytokines were higher in the AR group, but this elevation was not sustained and significantly decreased for the 14 days post-MI. In the RR group, the concentrations of cytokines did not change and stable for the 14 days post-MI. As a reflection of this findings, stable IL-10 concentration may play a role the improvement of cardiac functions.

1. Gullestad L, Ueland T, Vinge LE, Finsen A, Yndestad A, Aukrust P. Inflammatory cytokines in heart failure: mediators and markers. Cardiology. 2012;122(1):23–35. DOI: 10.1159/000338166

2. Khaper N, Bryan S, Dhingra S, Singal R, Bajaj A, Pathak CM et al. Targeting the Vicious Inflammation–Oxidative Stress Cycle for the Management of Heart Failure. Antioxidants & Redox Signaling. 2010;13(7):1033–49. DOI: 10.1089/ars.2009.2930

3. Frangogiannis NG. The Immune System and the Remodeling Infarcted Heart: Cell Biological Insights and Therapeutic Opportunities. Journal of Cardiovascular Pharmacology. 2014;63(3):185–95. DOI: 10.1097/FJC.0000000000000003

4. Kain V, Prabhu SD, Halade GV. Inflammation revisited: inflammation versus resolution of inflammation following myocardial infarction. Basic Research in Cardiology. 2014;109(6):444. DOI: 10.1007/s00395-014-0444-7

5. Jung M, Ma Y, Iyer RP, DeLeon-Pennell KY, Yabluchanskiy A, Garrett MR et al. IL-10 improves cardiac remodeling after myocardial infarction by stimulating M2 macrophage polarization and fibroblast activation. Basic Research in Cardiology. 2017;112(3):33. DOI: 10.1007/s00395-017-0622-5

6. Saraiva M, Vieira P, O’Garra A. Biology and therapeutic potential of interleukin-10. Journal of Experimental Medicine. 2020;217(1):e20190418. DOI: 10.1084/jem.20190418

7. Krishnamurthy P, Rajasingh J, Lambers E, Qin G, Losordo DW, Kishore R. IL-10 Inhibits Inflammation and Attenuates Left Ventricular Remodeling After Myocardial Infarction via Activation of STAT3 and Suppression of HuR. Circulation Research. 2009;104(2):e9–18. DOI: 10.1161/CIRCRESAHA.108.188243

8. Calegari L, Nunes RB, Mozzaquattro BB, Rossato DD, Dal Lago P. Exercise training improves the IL-10/TNF-α cytokine balance in the gastrocnemius of rats with heart failure. Brazilian Journal of Physical Therapy. 2018;22(2):154–60. DOI: 10.1016/j.bjpt.2017.09.004

9. Dhingra S, Sharma AK, Singla DK, Singal PK. p38 and ERK1/2 MAPKs mediate the interplay of TNF-α and IL-10 in regulating oxidative stress and cardiac myocyte apoptosis. American Journal of Physiology-Heart and Circulatory Physiology. 2007;293(6):H3524–31. DOI: 10.1152/ajpheart.00919.2007

10. Jones SP, Trocha SD, Lefer DJ. Cardioprotective actions of endogenous IL-10 are independent of iNOS. American Journal of Physiology-Heart and Circulatory Physiology. 2001;281(1):H48–52. DOI: 10.1152/ajpheart.2001.281.1.H48

11. Gallagher G, Dickensheets H, Eskdale J, Izotova L, Mirochnitchenko O, Peat J et al. Cloning, expression and initial characterisation of interleukin-19 (IL-19), a novel homologue of human interleukin-10 (IL-10). Genes & Immunity. 2000;1(7):442–50. DOI: 10.1038/sj.gene.6363714

12. Oral HB, Kotenko SV, Yılmaz M, Mani O, Zumkehr J, Blaser K et al. Regulation of T cells and cytokines by the interleukin-10 (IL-10)-family cytokines IL-19, IL-20, IL-22, IL-24 andIL-26. European Journal of Immunology. 2006;36(2):380–8. DOI: 10.1002/eji.200425523

13. Logsdon NJ, Deshpande A, Harris BD, Rajashankar KR, Walter MR. Structural basis for receptor sharing and activation by interleukin-20 receptor-2 (IL-20R2) binding cytokines. Proceedings of the National Academy of Sciences. 2012;109(31):12704–9. DOI: 10.1073/pnas.1117551109

14. Dumoutier L, Leemans C, Lejeune D, Kotenko SV, Renauld J-C. Cutting Edge: STAT Activation By IL-19, IL-20 and mda-7 Through IL20 Receptor Complexes of Two Types. The Journal of Immunology. 2001;167(7):3545–9. DOI: 10.4049/jimmunol.167.7.3545

15. Ellison S, Gabunia K, Kelemen SE, England RN, Scalia R, Richards JM et al. Attenuation of Experimental Atherosclerosis by Interleukin-19. Arteriosclerosis, Thrombosis, and Vascular Biology. 2013;33(10):2316–24. DOI: 10.1161/ATVBAHA.113.301521

16. Bruns DR, Ghincea AR, Ghincea CV, Azuma Y-T, Watson PA, Autieri MV et al. Interleukin-19 is cardioprotective in dominant negative cyclic adenosine monophosphate response-element binding proteinmediated heart failure in a sex-specific manner. World Journal of Cardiology. 2017;9(8):673–84. DOI: 10.4330/wjc.v9.i8.673

17. Stephen-Victor E, Fickenscher H, Bayry J. IL-26: An Emerging Proinflammatory Member of the IL-10 Cytokine Family with Multifaceted Actions in Antiviral, Antimicrobial, and Autoimmune Responses. PLOS Pathogens. 2016;12(6):e1005624. DOI: 10.1371/journal.ppat.1005624

18. Dambacher J, Beigel F, Zitzmann K, De Toni EN, Goke B, Diepolder HM et al. The role of the novel Th17 cytokine IL-26 in intestinal inflammation. Gut. 2009;58(9):1207–17. DOI: 10.1136/gut.2007.130112

19. Thygesen K, Alpert JS, Jaffe AS, Simoons ML, Chaitman BR, White HD et al. Third universal definition of myocardial infarction. Journal of the American College of Cardiology. 2012;60(16):1581–98. DOI: 10.1016/j.jacc.2012.08.001

20. Ibanez B, James S, Agewall S, Antunes MJ, Bucciarelli-Ducci C, Bueno H et al. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). European Heart Journal. 2018;39(2):119–77. DOI: 10.1093/eurheartj/ehx393

21. Reindl M, Reinstadler SJ, Tiller C, Feistritzer H-J, Kofler M, Brix A et al. Prognosis-based definition of left ventricular remodeling after ST-elevation myocardial infarction. European Radiology. 2019;29(5):2330–9. DOI: 10.1007/s00330-018-5875-3

22. Bulluck H, Go YY, Crimi G, Ludman AJ, Rosmini S, Abdel-Gadir A et al. Defining left ventricular remodeling following acute ST-segment elevation myocardial infarction using cardiovascular magnetic resonance. Journal of Cardiovascular Magnetic Resonance. 2017;19(1):26. DOI: 10.1186/s12968-017-0343-9

23. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clinical Chemistry. 1972;18(6):499–502. PMID: 4337382

24. Bohnen S, Avanesov M, Jagodzinski A, Schnabel RB, Zeller T, Karakas M et al. Cardiovascular magnetic resonance imaging in the prospective, population-based, Hamburg City Health cohort study: objectives and design. Journal of Cardiovascular Magnetic Resonance. 2018;20(1):68. DOI: 10.1186/s12968-018-0490-7

25. Zarrouk-Mahjoub S, Zaghdoudi M, Amira Z, Chebi H, Khabouchi N, Finsterer J et al. Pro- and anti-inflammatory cytokines in post-infarction left ventricular remodeling. International Journal of Cardiology. 2016;221:632–6. DOI: 10.1016/j.ijcard.2016.07.073

26. Meng D, Han S, Jeong IS, Kim SW. Interleukin 10–Secreting MSCs via TALENMediated Gene Editing Attenuates Left Ventricular Remodeling after Myocardial Infarction. Cellular Physiology and Biochemistry. 2019;52(4):728–41. DOI: 10.33594/000000051

27. Falcao RA, Christopher S, Oddi C, Reznikov L, Grizzard JD, Abouzaki NA et al. Interleukin-10 in patients with ST-segment elevation myocardial infarction. International Journal of Cardiology. 2014;172(1):e6–8. DOI: 10.1016/j.ijcard.2013.12.126

28. Burchfield JS, Iwasaki M, Koyanagi M, Urbich C, Rosenthal N, Zeiher AM et al. Interleukin-10 From Transplanted Bone Marrow Mononuclear Cells Contributes to Cardiac Protection After Myocardial Infarction. Circulation Research. 2008;103(2):203–11. DOI: 10.1161/CIRCRESAHA.108.178475

29. Qi L, Zhang J, Wu K, Shi S, Ji Q, Miao H et al. IL-19 as a Biomarker for the Severity of Acute Myocardial Infarction. Archives of Medical Research. 2020;51(2):160–6. DOI: 10.1016/j.arcmed.2020.01.007

30. England RN, Autieri MV. Anti-Inflammatory Effects of Interleukin-19 in Vascular Disease. International Journal of Inflammation. 2012;2012:253583. DOI: 10.1155/2012/253583

31. An W, Yu Y, Zhang Y, Zhang Z, Yu Y, Zhao X. Exogenous IL‐19 attenuates acute ischaemic injury and improves survival in male mice with myocardial infarction. British Journal of Pharmacology. 2019;176(5):699–710. DOI: 10.1111/bph.14549

32. Azuma Y-T, Matsuo Y, Kuwamura M, Yancopoulos GD, Valenzuela DM, Murphy AJ et al. Interleukin-19 protects mice from innate-mediated colonic inflammation: Inflammatory Bowel Diseases. 2010;16(6):1017–28. DOI: 10.1002/ibd.21151